NASDAQ:AGIO
Agios Pharmaceuticals Inc. (AGIO)
Financials 
Technical Analysis 
Sep 2, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Agios Pharmaceuticals Inc. (AGIO) has been under review from Stockchase Research Editor Michael O'Reilly, with two contrasting evaluations provided on August 14, 2025. The first review indicated a recent downturn, with the stock down by 7.3%, prompting a recommendation to cover the position at a stop price of $34. This decision stems from a discipline-focused approach, suggesting that while there has been some profitability, it is prudent to exit the position now. Conversely, the second review reflects a more optimistic outlook, highlighting a 28% increase and suggesting an adjustment of the stop price from $30 to $34 as the stock journey continues positively. The contrasting performances indicate volatility but also promise, with the stock showing potential for gains if managed carefully. Overall, these reviews suggest an intricate situation for investors considering AGIO.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPremium contentWe reiterate AGIO as a TOP PICK. The company continues development of rare disease treatments, including sickle cell with major products edging towards release this year. It trades at 3x earnings, 1.6x book and supports a robust 64% ROE. We recommend trailing up the stop (from $27) to $30, looking to achieve $48 -- upside potential of 29%. Yield 0%
(Analysts’ price target is $47.67)Premium contentWe reiterate AGIO as a TOP PICK. The pharma company continues moving forward on medications in the treatment of sickle cell disease and is a a lead candidate for FDA approvals. It trades at 3x earnings, 1.4x book and supports a 60% ROE. We recommend trailing up the stop (from $24) to $27, looking to achieve $46 -- 28% upside potential. Yield 0%
(Analysts’ price target is $51.71)Premium contentAGIO is a mid-sized pharma company with a long pipeline of projects continuing to advance towards commercialization -- including one for sickle cell. It trades at 3x earnings, 1.2x book and supports a robust 60% ROE. We like that cash reserves are growing, while product expenses increase. We recommend setting a stop-loss at $24, looking to achieve $39 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $52.43)Premium contentOur PAST TOP PICK with AGIO has triggered its stop at $25. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 23%, when combined with our previous guidance.
Premium contentWe reiterate AGIO as a TOP PICK. The developer of cancer treatment drugs expects two more products to go commercial over the next year- each with the potential to grow cash flows substantially. It trades at 3x earnings, 1.2x book and supports and supports a robust 57% ROE. We recommend trailing up the stop (from $21) to $25, looking to achieve $41 — upside potential of 28%. Yield 0%
(Analysts’ price target is $54.57)Premium contentAGIO is a biopharma company focusing on various cancer treatments. It continues to advance its pipeline of new rare disease treatments include one for anemia blood disorder. It has recently sold a royalty for one of its drugs that is increasing cash reserves dramatically. We like that it trades at 3x earnings, 1.2x book and supports a ROE of 53%. We recommend setting a stop-loss at $21, looking to achieve $43 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $57.00)- «
- ‹
- 1
- ›
- »
Popular Articles
Agios Pharmaceuticals Inc. (AGIO) Frequently Asked Questions
What is Agios Pharmaceuticals Inc. stock symbol?
Agios Pharmaceuticals Inc. is a American stock, trading under the symbol AGIO (previously AGIO-Q on Stockchase) on the NASDAQ (AGIO). It is usually referred to as NASDAQ:AGIO or AGIO
Is Agios Pharmaceuticals Inc. a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on AGIO (previously AGIO-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for Agios Pharmaceuticals Inc..
Is Agios Pharmaceuticals Inc. a good investment or a top pick?
Agios Pharmaceuticals Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-11-20. Read the latest stock experts ratings for Agios Pharmaceuticals Inc..
Why is Agios Pharmaceuticals Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Agios Pharmaceuticals Inc..
Is Agios Pharmaceuticals Inc. worth watching?
Agios Pharmaceuticals Inc. is followed by 15 investors on Stockchase and is a trending stock that is worth watching.
What is Agios Pharmaceuticals Inc. stock price?
On 2026-09-02, Agios Pharmaceuticals Inc. (AGIO) stock closed at a price of $34.13.
Our PAST TOP PICK with AGIO has triggered its stop at $34. To remain disciplined, we recommend covering the position at this time. Combined with previous guidance, this will result in a net investment gain of 1%.